Literature DB >> 20630868

Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells.

Shiam-Peng Tay1, Calvin W S Yeo, Chou Chai, Pei-Jou Chua, Hui-Mei Tan, Alex X Y Ang, Daniel L H Yip, Jian-Xiong Sung, Puay Hoon Tan, Boon-Huat Bay, Siew-Heng Wong, Carol Tang, Jeanne M M Tan, Kah-Leong Lim.   

Abstract

Although mutations in the parkin gene are frequently associated with familial Parkinsonism, emerging evidence suggests that parkin also plays a role in cancers as a putative tumor suppressor. Supporting this, we show here that parkin expression is dramatically reduced in several breast cancer-derived cell lines as well as in primary breast cancer tissues. Importantly, we found that ectopic parkin expression in parkin-deficient breast cancer cells mitigates their proliferation rate both in vitro and in vivo, as well as reduces the capacity of these cells to migrate. Cell cycle analysis revealed the arrestment of a significant percentage of parkin-expressing breast cancer cells at the G1-phase. However, we did not observe significant changes in the levels of the G1-associated cyclin D1 and E. On the other hand, the level of cyclin-dependent kinase 6 (CDK6) is dramatically and selectively elevated in parkin-expressing breast cancer cells, the extent of which correlates well with the expression of parkin. Interestingly, a recent study demonstrated that CDK6 restrains the proliferation of breast cancer cells. Taken together, our results support a negative role for parkin in tumorigenesis and provide a potential mechanism by which parkin exerts its suppressing effects on breast cancer cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20630868      PMCID: PMC2937954          DOI: 10.1074/jbc.M110.108241

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

1.  Down-regulation of parkin protein in transient focal cerebral ischemia: A link between stroke and degenerative disease?

Authors:  Thorsten Mengesdorf; Poul H Jensen; Gunter Mies; Christoph Aufenberg; Wulf Paschen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-01       Impact factor: 11.205

2.  WWOX, the FRA16D gene, behaves as a suppressor of tumor growth.

Authors:  A K Bednarek; C L Keck-Waggoner; R L Daniel; K J Laflin; P L Bergsagel; K Kiguchi; A J Brenner; C M Aldaz
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

3.  Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells.

Authors:  H Ishii; K R Dumon; A Vecchione; F Trapasso; K Mimori; H Alder; M Mori; G Sozzi; R Baffa; K Huebner; C M Croce
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

4.  Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity.

Authors:  John F Staropoli; Caroline McDermott; Cécile Martinat; Brenda Schulman; Elena Demireva; Asa Abeliovich
Journal:  Neuron       Date:  2003-03-06       Impact factor: 17.173

Review 5.  Common fragile sites and cancer (review).

Authors:  D I Smith; H Huang; L Wang
Journal:  Int J Oncol       Date:  1998-01       Impact factor: 5.650

6.  Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27.

Authors:  Rossano Cesari; Eric S Martin; George A Calin; Francesca Pentimalli; Roberta Bichi; Holly McAdams; Francesco Trapasso; Alessandra Drusco; Masayoshi Shimizu; Valeria Masciullo; Giuseppina D'Andrilli; Giovanni Scambia; Maria Cristina Picchio; Hansjuerg Alder; Andrew K Godwin; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-28       Impact factor: 11.205

7.  Identification of genes involved in cell invasion by using a library of randomized hybrid ribozymes.

Authors:  Eigo Suyama; Hiroaki Kawasaki; Motowo Nakajima; Kazunari Taira
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-28       Impact factor: 11.205

8.  Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies.

Authors:  Selvaraju Veeriah; Barry S Taylor; Shasha Meng; Fang Fang; Emrullah Yilmaz; Igor Vivanco; Manickam Janakiraman; Nikolaus Schultz; Aphrothiti J Hanrahan; William Pao; Marc Ladanyi; Chris Sander; Adriana Heguy; Eric C Holland; Philip B Paty; Paul S Mischel; Linda Liau; Timothy F Cloughesy; Ingo K Mellinghoff; David B Solit; Timothy A Chan
Journal:  Nat Genet       Date:  2009-11-29       Impact factor: 38.330

9.  Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer.

Authors:  Stacy R Denison; Gwen Callahan; Nicole A Becker; Leslie A Phillips; David I Smith
Journal:  Genes Chromosomes Cancer       Date:  2003-09       Impact factor: 5.006

10.  Alterations in the common fragile site gene Parkin in ovarian and other cancers.

Authors:  Stacy R Denison; Fang Wang; Nicole A Becker; Birgitt Schüle; Norman Kock; Leslie A Phillips; Christine Klein; David I Smith
Journal:  Oncogene       Date:  2003-11-13       Impact factor: 9.867

View more
  42 in total

Review 1.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

2.  ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer.

Authors:  Mary M Heckler; Hemang Thakor; Cara C Schafer; Rebecca B Riggins
Journal:  FEBS J       Date:  2014-04-28       Impact factor: 5.542

3.  Genomic and Functional Analysis of the E3 Ligase PARK2 in Glioma.

Authors:  De-Chen Lin; Liang Xu; Ye Chen; Haiyan Yan; Masaharu Hazawa; Ngan Doan; Jonathan W Said; Ling-Wen Ding; Li-Zhen Liu; Henry Yang; Shizhu Yu; Michael Kahn; Dong Yin; H Phillip Koeffler
Journal:  Cancer Res       Date:  2015-04-15       Impact factor: 12.701

4.  Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression.

Authors:  Juan Liu; Cen Zhang; Hao Wu; Xiao-Xin Sun; Yanchen Li; Shan Huang; Xuetian Yue; Shou-En Lu; Zhiyuan Shen; Xiaoyang Su; Eileen White; Bruce G Haffty; Wenwei Hu; Zhaohui Feng
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

5.  Parkin is transcriptionally regulated by the aryl hydrocarbon receptor: Impact on α-synuclein protein levels.

Authors:  Emmanuel González-Barbosa; Rosario García-Aguilar; Libia Vega; María Asunción Cabañas-Cortés; Frank J Gonzalez; José Segovia; Sara L Morales-Lázaro; Bulmaro Cisneros; Guillermo Elizondo
Journal:  Biochem Pharmacol       Date:  2019-08-09       Impact factor: 5.858

6.  The second genome: Effects of the mitochondrial genome on cancer progression.

Authors:  Adam D Scheid; Thomas C Beadnell; Danny R Welch
Journal:  Adv Cancer Res       Date:  2019-02-27       Impact factor: 6.242

7.  Implication of alterations in Parkin gene among North Indian patients with colorectal cancer.

Authors:  Raj Ranjan Tiwari; Khushnuma Wahabi; Ahmad Perwez; Zafar Iqbal Bhat; Syed Shamimul Hasan; Sundeep Singh Saluja; Moshahid Alam Rizvi
Journal:  Turk J Gastroenterol       Date:  2020-03       Impact factor: 1.852

8.  E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis.

Authors:  Valentina Montagnani; Luisa Maresca; Alessandro Apollo; Sara Pepe; Ryan M Carr; Martin E Fernandez-Zapico; Barbara Stecca
Journal:  J Biol Chem       Date:  2020-09-16       Impact factor: 5.157

Review 9.  An emerging role of PARK2 in cancer.

Authors:  Liang Xu; De-chen Lin; Dong Yin; H Phillip Koeffler
Journal:  J Mol Med (Berl)       Date:  2013-12-03       Impact factor: 4.599

Review 10.  Mitochondrial control of cell bioenergetics in Parkinson's disease.

Authors:  Raquel Requejo-Aguilar; Juan P Bolaños
Journal:  Free Radic Biol Med       Date:  2016-04-16       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.